|
PLACENTAL HISTOTHERAPY CENTER
History
In the 70's, in fulfillment of a commercial agreement, Cuba exported annually 40 tons of human placenta to MERIUX Laboratories, in France. At the same time, Dr. Carlos Miyares Cao, a physician specialist in Gynecology, Obstetrics and Pharmacology, and professor from Medical School of the University of Havana, Cuba, discovers a substance which stimulates skin pigmentation activity, while studying live placental metabolism under laboratory conditions.
The successful use in our country of that substance in the treatment of the skin disease known as Vitiligo, decided to discontinue around 1980-1982 the exports of placenta to France, to begin, within the National Pharmaceutical Industry, the production of the new medicine known as Melagenina for its distribution in pharmacies on medical prescription.
In 1985, the first international service of Vitiligo patients was created at the “Cira García” Clinic, in Havana City, in charge of Dr. Carlos Miyares Cao. The great flow of nearby country patients to Cuba (Mexico, Venezuela, Colombia, etc.,) gave rise to establish the first system of health tourism through CUBATUR Company.
In 1986, due to the international repercussion of the new Cuban method for the treatment of Vitiligo, by which a medicine obtained from human placenta was used, the Council of State creates the Placental Histotherapy Center headed by Dr. Carlos Miyares Cao for further research.
In 1987, it was necessary to establish the International and National Clinical Service for Vitiligo patients due to an increase in the number of foreign patients requesting to be treated in Cuba with the new medicine (100 patients monthly, from more than 90 countries), as well as to treat Cuban patients suffering this disease throughout the country. From 1988 to 1991, centers for the medical treatment of these patients, began to be established in other countries, and therefore the export of Melagenina started.
The medical staff of those centers were trained at the Placental Histotherapy Center so as to guarantee the same efficiency in the application of the method as in Cuba.
Consequently, there were centers at the Canary Islands (Spain), Republic of San Marino, Madrid, (Spain); Brazil; Bogota, (Colombia); Mexico City, (Mexico); Lima, (Peru); Nicaragua; El Salvador; Entre Ríos, (Argentina); Kiev, (Ukraine); Moscow and Petrograd (Russia); Kirghiz; Kazakhstan; Riga; Latvia; Nigeria, (Africa).
At this stage, 30 Vitiligo patient associations known as “Friendly Associations against Vitiligo” were established, and formed by sick people requesting the introduction of the Cuban drug in their respective countries.
From 1992 to 1994, our government analysed the need of building a manufacturing plant for the production of different medicines from human placenta, not only the Melagenina, but also other useful medicines for the treatment of other pathologies as well as cosmetics that have proved to be of great efficiency in delaying the cell aging process. This was the result of the work developed by Dr. Carlos Miyares Cao and his research team from the Placental Histotherapy Center, who obtained new medicines, such as:
Period from 1970 to 1980
Melagenina (for Vitiligo treatment)
Coriodermina (for Psoriasis treatment)
Piloactive lotion (for Alopecia treatment)
Period from 1980 to 1990
¨ Tromboplastine (blood coagulation)
¨ Dietary Supplement (osteoporosis - anaemia)
1980 - 1994
¨ Melagenina Plus (for Vitiligo treatment optimization)
¨ Enteral Food (intensive care)
¨ Tensoactive Lung Surfactant (neonatology)
¨ Placental lactogen (Obstetrics)
Cosmetics Period from 1980 to 1990
¨ Placental Shampoo
¨ Bioactive Dermal Cream (dermothrophic)
¨ Bioactive Dermal Gel
¨ Epidermic Photoprotecting Gel
Period from 1990 to 1994
¨ Amniotic Collagen Cream
¨ Hair Conditioner
¨ Facial Tonics
¨ Cleaning Milks
¨ Bioactive Dermal Soap
Previous to the construction of the manufacturing plant of the center, these products were prepared by the following institutions: Melagenina, the Piloactive Lotion and the Placental Shampoo in facilities of the pharmaceutical medical industry at manufacturing, packaging and quality control units located in different places, hindering thus the increase and large scale production, while the Coriodermina and the remaining cosmetics were developed at the research area of the center with better technological conditions but with home poor productive capacity. Consequently, it was increasingly difficult to cover the home and international demand of these placental by-products.
Therefore, a manufacturing plant with modern technology and high productive capacity began to be built in 1991 in the municipality of La Lisa in the near of Valle Grande in Havana City. The construction works were assigned to ECOA-25, a brigade from the Ministery of Construction (MICONS), and this project was directly supervised by the Investment Division of the Council of State.
The construction lasted 4 years, the investment area covers 26 000 m2 and it is mainly constituted by two parallel buildings.
The main building has the necessary equipment for storing and unfreezing the placenta collected from the Gynecology and Obstetrics hospitals of the country; extraction and bioprocessing of the different above-mentioned placental by-products, as well as their packing and storage for their subsequent distribution both in the country and abroad.
The Laboratories for Chemical Quality Control, Microbiological and Biological Laboratories and area for developing new technologies are in the second building.
The approved staff is of 170 workers and their theoretical productive capacity is 3000 flasks per hour.
The ENSUFARMA Co. is responsible for the distribution of the end products throughout the country for national consumption. The Heber Biotec Co. is entrusted with their marketing abroad.
Now the Placental Histotherapy Center has two areas:
1. RESEARCH AND CLINICAL SERVICE
Main tasks:
· Medical Services for Cuban and foreign patients suffering from Vitiligo, Psoriasis and Alopecia.
· Search for new medicines and cosmetics obtained from the human placenta.
· Optimization of the currently used treatments for Vitiligo, Psoriasis and Alopecia.
· In-depth study of the etiology of such diseases.
· Establishment of laboratory methods of analysis to determine the quality of the human placenta by-products.
· Medical post-graduate teaching.
2. MANAGEMENT AND PRODUCTION OF THE COMPANY
Main objectives:
· Marketing of the products obtained from the human placenta.
· Production of drugs, cosmetics, nutrients and indicators extracted from the human placenta.
· Technological scaling of the new products.
|
